SONNET BIOTHERAPEUTICS HOLDI (SONN) Stock Price & Overview
NASDAQ:SONN • US83548R4020
Current stock price
The current stock price of SONN is 1.26 USD. Today SONN is down by -59.35%. In the past month the price decreased by -68.73%. In the past year, price decreased by -40%.
SONN Key Statistics
- Market Cap
- 8.921M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -7.23
- Dividend Yield
- N/A
SONN Stock Performance
SONN Stock Chart
SONN Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to SONN. When comparing the yearly performance of all stocks, SONN is a bad performer in the overall market: 95.03% of all stocks are doing better.
SONN Earnings
SONN Forecast & Estimates
7 analysts have analysed SONN and the average price target is 20.4 USD. This implies a price increase of 1519.05% is expected in the next year compared to the current price of 1.26.
SONN Groups
Sector & Classification
SONN Financial Highlights
Over the last trailing twelve months SONN reported a non-GAAP Earnings per Share(EPS) of -7.23. The EPS increased by 70.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -659.57% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
SONN Ownership
SONN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SONN
Company Profile
Sonnet BioTherapeutics Holdings, Inc. is a clinical stage biotechnology company, which engages in the innovation of biologic medicines. The company is headquartered in Princeton, New Jersey and currently employs 13 full-time employees. The company went IPO on 2005-07-27. The Fully Human Albumin Binding (FHAB), a technology which utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its FHAB is designed to specifically target tumor and lymphatic tissue. The firm's lead program, SON-1010, or IL-12-FHAB, is in development for the treatment of solid tumors and ovarian cancer. SON-1010 is being evaluated in an ongoing Phase 1/2a study, in combination with atezolizumab (Tecentriq) for the treatment of platinum-resistant ovarian cancer (PROC). The firm is also evaluating its second program, SON-1210, an IL12-FHAB-IL15 for solid tumor. Its SON-080 program is a low dose of rhIL-6 in development for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN).
Company Info
IPO: 2005-07-27
SONNET BIOTHERAPEUTICS HOLDI
100 Overlook Center, Suite 102
Princeton NEW JERSEY 08540 US
CEO: Pankaj Mohan
Employees: 13
Phone: 16093752227
SONNET BIOTHERAPEUTICS HOLDI / SONN FAQ
Can you describe the business of SONNET BIOTHERAPEUTICS HOLDI?
Sonnet BioTherapeutics Holdings, Inc. is a clinical stage biotechnology company, which engages in the innovation of biologic medicines. The company is headquartered in Princeton, New Jersey and currently employs 13 full-time employees. The company went IPO on 2005-07-27. The Fully Human Albumin Binding (FHAB), a technology which utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its FHAB is designed to specifically target tumor and lymphatic tissue. The firm's lead program, SON-1010, or IL-12-FHAB, is in development for the treatment of solid tumors and ovarian cancer. SON-1010 is being evaluated in an ongoing Phase 1/2a study, in combination with atezolizumab (Tecentriq) for the treatment of platinum-resistant ovarian cancer (PROC). The firm is also evaluating its second program, SON-1210, an IL12-FHAB-IL15 for solid tumor. Its SON-080 program is a low dose of rhIL-6 in development for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN).
What is the stock price of SONNET BIOTHERAPEUTICS HOLDI today?
The current stock price of SONN is 1.26 USD. The price decreased by -59.35% in the last trading session.
What is the dividend status of SONNET BIOTHERAPEUTICS HOLDI?
SONN does not pay a dividend.
What is the ChartMill rating of SONNET BIOTHERAPEUTICS HOLDI stock?
SONN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the GICS sector and industry of SONN stock?
SONNET BIOTHERAPEUTICS HOLDI (SONN) operates in the Health Care sector and the Biotechnology industry.
When does SONNET BIOTHERAPEUTICS HOLDI (SONN) report earnings?
SONNET BIOTHERAPEUTICS HOLDI (SONN) will report earnings on 2025-12-15, after the market close.